Darlene Dobkowski, MA

The quality-of-life improvement with Abecma in patients with relapsed/refractory multiple myeloma was greater when compared with standard regimens.

CURE® honored eight MPN Heroes, which ranged from medical professionals to patients and caregivers, on the contributions they made in the field.

The recent FDA approval of the next-generation tyrosine kinase inhibitor Augtyro provides patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer another treatment option when the disease becomes resistant to other therapies.

If metastatic breast cancer no longer responds to a given therapy, finding out what targetable mutations a patient has may guide the next steps for treatment, an expert said.

The FDA recently approved Tibsovo for relapsed/refractory MDS with an IDH1 mutation, a treatment option for a disease subset with no options before this approval.

In conjunction with ZERO — The End of Prostate Cancer, CURE® recently hosted the “Educated Patient® Webinar: Advancing Equity in Prostate Cancer Care.”

Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.

Circulating tumor DNA — which is observed via blood test — may be helpful in determining which patients with kidney cancer need more intense treatment and who can have their therapies deescalated.

While translocation renal cell carcinoma tends to respond well to immunotherapy, there is still a need for more investigation into targeted therapies for this patient population.

An expert explained the different treatment options for patients with estrogen receptor-positive, HER2-negative breast cancer that has recently been diagnosed or has recurred.

Managing side effects from lung cancer treatment with dose reductions is an approach experts have been using more, even though some patients voice concerns about lowering a drug’s impact on the disease.

An expert explained how next-generation sequencing can help patients with metastatic breast cancer understand their disease and available treatment options.

There are three types of myeloproliferative neoplasms, all of which come with their own set of symptoms and management strategies.

Treating patients with Tagrisso, a tyrosine kinase inhibitor, plus chemotherapy reduced the progression risk of disease of the central nervous system in patients with EGFR-positive non-small cell lung cancer.

This expanded indication broadens the use of Rozlytrek for solid tumors to include children one month old, with the original approval in 2019 only including children one year and older.

Patients with previously treated small cell lung cancer who received a 10-mg dose of tarlatamab had improved responses with no new safety signals.

One expert explained how patients with breast cancer have an increased risk for blood clots, even though one recently published survey determined that not many patients are aware of this.

The FDA approved Opdivo for the treatment of patients aged 12 years and older with stage 2B or 2C melanoma that has been surgically removed

Adding TPST-1120 to the standard of care for the treatment of unresectable or metastatic hepatocellular carcinoma, a type of liver cancer, improved progression-free survival and overall survival in a phase 1b/2 clinical study.

After discussions with the FDA, Takeda plans on voluntarily withdrawing Exkivity as a treatment for adults with EGFR exon 20 insertion mutation-positive, locally advanced or metastatic non-small cell lung cancer.

Now in its fifth edition, “The Complete Guide to Breast Reconstruction: Choosing the Best Options After Your Mastectomy” by two-time breast cancer survivor Kathy Steligo offers patients comprehensive, up-to-date information.

A woman with stage 4 inflammatory breast cancer details her journey with the disease and why it is important for patients to ask questions about anything going on with their bodies.

Patients with chronic lymphocytic leukemia treated with Imbruvica plus Venclexta demonstrated a healthy immune profile over time in addition to reduction in CLL disease burden.

"I’m on a healthy footing, and that’s pretty miraculous," said singer-songwriter Andrew McMahon, an acute lymphoblastic leukemia survivor and founder of the Dear Jack Foundation.

An expert explained the benefits of proton therapy for the treatment of prostate cancer, which delivers radiation directly to the tumor and spares surrounding areas.

Patients treated with 12 months of Lixiana, an anticoagulant therapy, received a greater benefit than those treated with three months of the therapy.

The recent publication of a guideline recommending mindfulness-based interventions highlight how important it is as a tactic to address symptoms of anxiety and depression in patients with cancer.

With surgical techniques applicable to many stages of kidney cancer, it is important for patients to discuss these options with their cancer team to select the best approach for their disease.

Elrexfio has been shown to provide patients with relapsed/refractory multiple myeloma who previously received four or more lines of therapy with a response that may last at least 15 months, an expert explained.

The recent FDA approval of Talvey for heavily pretreated multiple myeloma results in an improved response to therapy and a manageable side effect profile.